BRPI0407292A - Uso de um ácido nucleico, da correlação direta entre a super-expressão ou a modificação molecular funcional de homólogos humanos da famìlia sgk e a extensão do intervalo q/t, de um anticorpo dirigido contra um substrato de um homólogo humano da famìlia sgk, de um ativador funcional, ou de um regulador de transcrição positivo, de um homólogo humano da famìlia sgk e uso de substâncias selecionadas dentre o grupo consistindo de glucocorticóides, mineralocorticóides, aldosterona, gonadotropinas e citocinas, kit e método para diagnosticar hipertensão, kit para diagnosticar a sìndrome de qt longo e fármaco - Google Patents
Uso de um ácido nucleico, da correlação direta entre a super-expressão ou a modificação molecular funcional de homólogos humanos da famìlia sgk e a extensão do intervalo q/t, de um anticorpo dirigido contra um substrato de um homólogo humano da famìlia sgk, de um ativador funcional, ou de um regulador de transcrição positivo, de um homólogo humano da famìlia sgk e uso de substâncias selecionadas dentre o grupo consistindo de glucocorticóides, mineralocorticóides, aldosterona, gonadotropinas e citocinas, kit e método para diagnosticar hipertensão, kit para diagnosticar a sìndrome de qt longo e fármacoInfo
- Publication number
- BRPI0407292A BRPI0407292A BR0407292-8A BRPI0407292A BRPI0407292A BR PI0407292 A BRPI0407292 A BR PI0407292A BR PI0407292 A BRPI0407292 A BR PI0407292A BR PI0407292 A BRPI0407292 A BR PI0407292A
- Authority
- BR
- Brazil
- Prior art keywords
- sgk
- human
- syndrome
- kit
- homologue
- Prior art date
Links
- 208000004731 long QT syndrome Diseases 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 239000012190 activator Substances 0.000 title abstract 3
- 238000012986 modification Methods 0.000 title abstract 3
- 230000004048 modification Effects 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 230000002018 overexpression Effects 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title abstract 2
- 230000002103 transcriptional effect Effects 0.000 title abstract 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 title 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 102000006771 Gonadotropins Human genes 0.000 title 1
- 108010086677 Gonadotropins Proteins 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 title 1
- 229960002478 aldosterone Drugs 0.000 title 1
- 239000003862 glucocorticoid Substances 0.000 title 1
- 239000002622 gonadotropin Substances 0.000 title 1
- 229940094892 gonadotropins Drugs 0.000 title 1
- 239000002395 mineralocorticoid Substances 0.000 title 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 title 1
- 239000000758 substrate Substances 0.000 title 1
- 229940037128 systemic glucocorticoids Drugs 0.000 title 1
- 238000003745 diagnosis Methods 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 4
- 125000003729 nucleotide group Chemical group 0.000 abstract 4
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102100032616 Caspase-2 Human genes 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 101000867612 Homo sapiens Caspase-2 Proteins 0.000 abstract 1
- 206010020852 Hypertonia Diseases 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10305213A DE10305213A1 (de) | 2003-02-07 | 2003-02-07 | Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms |
| PCT/EP2004/001051 WO2004070057A2 (de) | 2003-02-07 | 2004-02-05 | Verwendung eines neuen polymorphismus im hsgk1-gen zur diagnose der hypertonie und verwendung der sgk-genfamilie zur diagnose und therapie des long-q/t-syndroms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0407292A true BRPI0407292A (pt) | 2006-01-31 |
Family
ID=32747646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0407292-8A BRPI0407292A (pt) | 2003-02-07 | 2004-02-05 | Uso de um ácido nucleico, da correlação direta entre a super-expressão ou a modificação molecular funcional de homólogos humanos da famìlia sgk e a extensão do intervalo q/t, de um anticorpo dirigido contra um substrato de um homólogo humano da famìlia sgk, de um ativador funcional, ou de um regulador de transcrição positivo, de um homólogo humano da famìlia sgk e uso de substâncias selecionadas dentre o grupo consistindo de glucocorticóides, mineralocorticóides, aldosterona, gonadotropinas e citocinas, kit e método para diagnosticar hipertensão, kit para diagnosticar a sìndrome de qt longo e fármaco |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080015141A1 (enExample) |
| EP (1) | EP1594983A2 (enExample) |
| JP (1) | JP2006520587A (enExample) |
| KR (1) | KR20050118672A (enExample) |
| CN (1) | CN1761760A (enExample) |
| AU (1) | AU2004209609A1 (enExample) |
| BR (1) | BRPI0407292A (enExample) |
| CA (1) | CA2515339A1 (enExample) |
| DE (1) | DE10305213A1 (enExample) |
| MX (1) | MXPA05008329A (enExample) |
| PL (1) | PL378400A1 (enExample) |
| RU (1) | RU2005127807A (enExample) |
| WO (1) | WO2004070057A2 (enExample) |
| ZA (1) | ZA200506283B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5071998B2 (ja) * | 2005-08-25 | 2012-11-14 | 学校法人日本大学 | 本態性高血圧症の判定方法 |
| WO2007025792A1 (de) * | 2005-09-02 | 2007-03-08 | Florian Lang | Verfahren zur diagnose von hypertonie |
| EP2090588A4 (en) | 2006-10-23 | 2010-04-07 | Neocodex S L | IN VITRO PROCEDURE FOR THE PROGNOSIS AND / OR DIAGNOSIS OF OVER SENSITIVITY TO ESTROGENIC OR SUBSTANCES WITH ESTROGENIC EFFECT |
| AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| CN101892311B (zh) * | 2010-06-01 | 2013-02-27 | 首都医科大学附属北京安贞医院 | 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒 |
| WO2015048531A1 (en) | 2013-09-26 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Inhibition of sgk1 in the treatment of heart conditions |
| JP2020526192A (ja) | 2017-07-06 | 2020-08-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | アルファ−ＥＮａＣの発現を阻害するためのＲＮＡｉ剤、および使用方法 |
| KR101992796B1 (ko) * | 2018-02-19 | 2019-06-26 | 한국 한의학 연구원 | Sgk1 유전자의 메틸화 수준을 이용한 고혈압의 예측 또는 진단을 위한 정보제공방법 및 이를 위한 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| DE69937159T2 (de) * | 1998-12-14 | 2008-06-26 | University Of Dundee, Dundee | Verfahren zur Aktivierung von SGK durch Phosphorylierung. |
| DE10113876A1 (de) * | 2001-03-21 | 2002-09-26 | Eberhard Karls Uni Medizinisch | Quantitative diagnostische Analyse der Hypertonie |
| DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
-
2003
- 2003-02-07 DE DE10305213A patent/DE10305213A1/de not_active Withdrawn
-
2004
- 2004-02-05 CN CNA2004800070352A patent/CN1761760A/zh active Pending
- 2004-02-05 BR BR0407292-8A patent/BRPI0407292A/pt not_active IP Right Cessation
- 2004-02-05 WO PCT/EP2004/001051 patent/WO2004070057A2/de not_active Ceased
- 2004-02-05 JP JP2006501739A patent/JP2006520587A/ja active Pending
- 2004-02-05 PL PL378400A patent/PL378400A1/pl not_active Application Discontinuation
- 2004-02-05 EP EP04708317A patent/EP1594983A2/de not_active Withdrawn
- 2004-02-05 KR KR1020057014578A patent/KR20050118672A/ko not_active Withdrawn
- 2004-02-05 US US10/544,576 patent/US20080015141A1/en not_active Abandoned
- 2004-02-05 AU AU2004209609A patent/AU2004209609A1/en not_active Abandoned
- 2004-02-05 CA CA002515339A patent/CA2515339A1/en not_active Abandoned
- 2004-02-05 RU RU2005127807/13A patent/RU2005127807A/ru not_active Application Discontinuation
- 2004-02-05 MX MXPA05008329A patent/MXPA05008329A/es unknown
-
2005
- 2005-08-05 ZA ZA200506283A patent/ZA200506283B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004070057A2 (de) | 2004-08-19 |
| US20080015141A1 (en) | 2008-01-17 |
| KR20050118672A (ko) | 2005-12-19 |
| PL378400A1 (pl) | 2006-04-03 |
| CN1761760A (zh) | 2006-04-19 |
| EP1594983A2 (de) | 2005-11-16 |
| MXPA05008329A (es) | 2005-09-30 |
| CA2515339A1 (en) | 2004-08-19 |
| ZA200506283B (en) | 2006-05-31 |
| DE10305213A1 (de) | 2004-08-26 |
| AU2004209609A1 (en) | 2004-08-19 |
| WO2004070057A3 (de) | 2004-11-25 |
| RU2005127807A (ru) | 2006-03-20 |
| JP2006520587A (ja) | 2006-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Subauste et al. | Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein β-catenin with the scaffolding protein MAGI-2 | |
| Janzen et al. | Unusual histone modifications in Trypanosoma brucei | |
| David et al. | MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine | |
| DK0759927T3 (da) | Pteridinnucleotidanaloger som fluorescerende DNA prober | |
| Lai et al. | Downregulation of eNOS mRNA expression by TNFα: identification and functional characterization of RNA–protein interactions in the 3′ UTR | |
| Garlet et al. | Expression of suppressors of cytokine signaling in diseased periodontal tissues: a stop signal for disease progression? | |
| BR0114575A (pt) | Sonda de hibridização de ácido nucléico de filamento duplo, reação de amplificação e detecção em tempo real, e, ensaio para detectar uma seq ência alvo de ácido nucléico | |
| DK1470144T3 (da) | Oligonukleotider omfattende alternerende segmenter og anvendelser deraf | |
| ATE334657T1 (de) | Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide | |
| Tower et al. | Fra‐1 targets the AP‐1 site/2G single nucleotide polymorphism (ETS site) in the MMP‐1 promoter | |
| DE60216798D1 (de) | Azyklische linker enthaltende oligonukleotide und deren verwendungen | |
| Ramon et al. | Effects of 8-oxo-7, 8-dihydro-2′-deoxyguanosine on the binding of the transcription factor Sp1 to its cognate target DNA sequence (GC box) | |
| Lee et al. | RNA annealing activity is intrinsically associated with U2AF | |
| WO2002069947A3 (en) | Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer | |
| BR9908215A (pt) | Derivados de ácidos hidroxâmico e carboxìlico | |
| ATE275956T1 (de) | Veränderung der dns methyltransferase durch kombinationstherapie | |
| BRPI0407292A (pt) | Uso de um ácido nucleico, da correlação direta entre a super-expressão ou a modificação molecular funcional de homólogos humanos da famìlia sgk e a extensão do intervalo q/t, de um anticorpo dirigido contra um substrato de um homólogo humano da famìlia sgk, de um ativador funcional, ou de um regulador de transcrição positivo, de um homólogo humano da famìlia sgk e uso de substâncias selecionadas dentre o grupo consistindo de glucocorticóides, mineralocorticóides, aldosterona, gonadotropinas e citocinas, kit e método para diagnosticar hipertensão, kit para diagnosticar a sìndrome de qt longo e fármaco | |
| Sikora et al. | Loss of transcription factor AP-1 DNA binding activity during lymphocyte aging in vivo | |
| ATE330031T1 (de) | Reversibel inhibierende sonden | |
| BR0308634A (pt) | Uso de um adenovìrus, e, composição | |
| BR9910678A (pt) | Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto | |
| Keen et al. | Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells | |
| Nemoto et al. | Differential induction of collagens by mechanical stress in human periodontal ligament cells | |
| Li et al. | Essential role for cathepsin D in bleomycin-induced apoptosis of alveolar epithelial cells | |
| DE60029225D1 (de) | Zusammensetzungen und verfahren zu höhere empfindlichkeit und spezifität von nukleinsäuresynthese |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |